Victory Capital Management Inc. Has $361,000 Stock Holdings in Embecta Corp. (NASDAQ:EMBC)

Victory Capital Management Inc. lifted its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 5.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,489 shares of the company’s stock after buying an additional 923 shares during the period. Victory Capital Management Inc.’s holdings in Embecta were worth $361,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of EMBC. Smartleaf Asset Management LLC grew its stake in shares of Embecta by 175.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company’s stock worth $25,000 after buying an additional 774 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Embecta by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 145,269 shares of the company’s stock valued at $2,048,000 after acquiring an additional 1,600 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Embecta by 5.7% during the 3rd quarter. Natixis Advisors LLC now owns 30,735 shares of the company’s stock valued at $433,000 after acquiring an additional 1,648 shares in the last quarter. Quarry LP bought a new stake in Embecta during the 3rd quarter worth $30,000. Finally, Rockefeller Capital Management L.P. increased its holdings in Embecta by 3.7% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 90,072 shares of the company’s stock worth $1,270,000 after purchasing an additional 3,231 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $12.82 on Friday. The firm has a market cap of $745.28 million, a PE ratio of 12.82, a price-to-earnings-growth ratio of 0.78 and a beta of 1.27. Embecta Corp. has a 52 week low of $9.93 and a 52 week high of $21.48. The firm’s fifty day moving average is $15.94 and its 200-day moving average is $16.37.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. Sell-side analysts forecast that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a $0.15 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.68%. Embecta’s dividend payout ratio (DPR) is currently 60.00%.

Insider Activity

In related news, Director Milton Mayo Morris sold 3,100 shares of Embecta stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $16.38, for a total transaction of $50,778.00. Following the completion of the transaction, the director now owns 36,133 shares of the company’s stock, valued at $591,858.54. This trade represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Wednesday, November 27th. Morgan Stanley upgraded shares of Embecta from an “underweight” rating to an “equal weight” rating and raised their price objective for the company from $13.00 to $20.00 in a report on Monday, December 2nd.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.